Synonyms:NVP-BGJ398, Infigratinib, 872511-34-7, BGJ398, BGJ-398, BGJ 398, Truseltiq, Infigratinib [INN], Infigratinib free base, 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea, Infigratinib [USAN], BGJ398 (NVP-BGJ398), MVP-BGJ398, NVP-BGJ398(Infigratinib), A4055ME1VK, CHEBI:63451, 872511-34-7 (free base), 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-{[4-(4-ethylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)-1-methylurea, 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-[6-[4-(4-ethylpiperazin-1-yl)anilino]pyrimidin-4-yl]-1-methylurea, Urea, N'-(2,6-dichloro-3,5-dimethoxyphenyl)-N-(6-((4-(4-ethyl-1-piperazinyl)phenyl)amino)-4-pyrimidinyl)-N-methyl-, CHEMBL1834657, 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-((4-(4-ethylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)-1-methylurea., 3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-[6-[[4-(4-ethylpiperazin-1-yl)phenyl]amino]pyrimidin-4-yl]-1-methylurea, UNII-A4055ME1VK, Infigratinib (BGJ398), Infigratinib (USAN/INN), Infigratinib [USAN:INN], NVP-BGJ389, 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)phenylamino)pyrimidin-4-yl)-1-methylurea, MLS006010953, INFIGRATINIB [WHO-DD], SCHEMBL374435, GTPL7877, CHEMBL1852688, DTXSID70236238, EX-A057, HMS3295O21, AMY10737, BCP03602, BGJ398 - NVP-BGJ398, BDBM50355393, FD5035, MFCD22123241, NSC764487, s2183, WHO 10032, AKOS025149513, AKOS032949944, BCP9000399, CS-0586, DB11886, NSC-764487, SB16612, NCGC00274030-01, NCGC00274030-11, 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea, AC-28417, AS-16290, HY-13311, SMR004702757, BCP0726000187, FT-0699366, D11589, J-510477, BRD-K42728290-001-01-8, Q27075200, 07J, 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea, N'-(2,6-DICHLORO-3,5-DIMETHOXYPHENYL)-N-(6-((4-(4-ETHYL-1- PIPERAZINYL)PHENYL)AMINO)-4-PYRIMIDINYL)-N-METHYLUREA
Id:53235510
Description:nan
